Innovating Antibodies, Improving Lives

Investor Presentation

December 2020

Forward Looking Statement

This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

2

Our Core Purpose, Strategy & Vision Guide Our Work

The Genmab Difference

4

Track Record & Growth

38 Cumulative INDs since 1999

Dual-listed in US & DK with 2019 US IPO

5

Solid Foundation Built on a Differentiated Pipeline

Potential 1st-in-Class/Best-in-Class

Our Own Clinical Pipeline

• • Tisotumab Vedotin5

• • Epcoritamab (DuoBody®-CD3xCD20)6

• • DuoBody-PD-L1x4-1BB7

R&D Engine

(innovaTV

Technologies & Pre-Clinical

• • DuoBody technology 206) study

• • HexaBody technology in

• • HexElect® technology

• • DuoHexaBody® technology population

• • DuoBody-CD40x4-1BB7

• • HexaBody®-DR5/DR5

• • DuoHexaBody®-CD376

• • DuoBody-CD3x5T46

Japanese

• • Rich Pre-Clinical Pipeline incl. HexaBody-CD388

Solid Financial Base

Approved Partnered Products

•DARZALEX® (daratumumab) / DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)1

•Kesimpta® (ofatumumab)2 •TEPEZZA® (teprotumumab)3 •Arzerra® (ofatumumab)4

Programs Built on Genmab's Innovation

Partner-owned Programs in the Clinic

• • 15 product candidates in clinical development w/ partners

• • Incl. 7 DuoBody products with Janssen, 1 with Novo Nordisk

6

1In dev. by Janssen; 2 in dev. by Novartis; 3In dev. by Horizon; 4Commercialized by Novartis, no longer in active development. 550:50 w/ Seagen; 650:50 w/ AbbVie; 750:50 w/ BioNTech, GEN1046 & GEN1042 respectively; 8Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc

DARZALEX® (daratumumab) & DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj): Redefining Treatment of Multiple Myeloma

First-in-class CD38 antibody in development to treat cancer

Collaboration with Janssen: Genmab entitled to tiered royalty of 12-20% of net sales

Approved in certain territories for various multiple myeloma (MM) indications1

DARZALEX FASPRO first and only SubQ CD38 mAb approved in U.S. for treatment of MM

2019 WW net sales by J&J: $2,998M

7

See local country prescribing information for approved indications

DARZALEX Approvals: US and EU

On Track for Approval Across All Lines of MM Treatment

Daratumumab

Proving to be the Critical Driver Across Different Combinations & Treatment Lines

Frontline

Relapsed/Refractory

Ongoing Phase 3: CEPHEUS (D-VRd, NDMM NTE), PERSEUS (D-VRd, NDMM TE)

3Data as per ASCO 2019; 4Data as per ASH 2019

9

Improved Survival for Patients with Multiple Myeloma

Overall Survival Analysis from ALCYONE Trial

Kaplan-Meier estimates of overall survival in intention-to-treat population. Mateos, MV et al, 'Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomized, open-label, phase 3 trial,' The Lancet, published online December 9, 2019

Kesimpta® (ofatumumab)

Approved in Relapsing Multiple Sclerosis

Human CD20 Antibody - well validated target

Injection for SubQ use approved for RMS in the US

First B-cell therapy that can be self-administered by patients at home using Sensoready® autoinjector pen

Second Genmab-created product with blockbuster potential

Developed by Novartis: Regulatory submission also

made in EU

Genmab 10% royalty payment of net sales

Tisotumab Vedotin

Genmab's Most Advanced Asset with Potential in Solid Tumors

Fully human antibody-drug conjugate (ADC) targeting Tissue Factor (TF) in development to treat solid tumors

License and collaboration agreement with Seattle

Genetics 50:50

Very favorable topline results, Phase 2 recurrent or metastatic cervical cancer

Ongoing trials in cervical, ovarian cancer, other solid tumors

Expanding development, additional studies planned

Tisotumab Vedotin in Cervical Cancer Designed to Address a High Unmet Medical Need

• • Poor prognosis advanced / recurrent cervical cancer

  • • RR standard therapies generally <15%

  • • Median OS 6-8 months

• • Data ORR & survival after progression on 1L bevacizumab + doublet chemotherapy are limited

• • Compelling and durable antitumor activity with manageable and tolerable safety profile

• • ORR 24%; CR: 7%

• • Median DOR 8.3 mo

• • Median PFS (4.2 mo) and OS (12.1 mo) encouraging

Clinically meaningful and durable responses observed*

0

*Data from innovaTV 204 study, Coleman R, et al. Tisotumab Vedotin in Cpreviously Treated Recurrent or Metastatic Cervical Cancer: Results from the Phase 2 innovaTV 204 / GOG-3023/ ENGOT-cx6 Study, ESMO September 21, 2020. Data cutoff: February 06, 2020. Median13 duration of follow-up: 10.0 months. CI, confidence interval; CR, complete response; DOR, duration of response; IRC, independent review committee; NR, not reached; ORR, objective response rate; PD, disease progression; PR, partial response; SD, stable disease.

Epcoritamab (DuoBody-CD3xCD20)

Potential for Improved Efficacy & Safety in B Cell Malignancies

Potential best-in-class therapeutic

T cell-mediated killing of CD20-expressing cells

SubQ Ph 3 trial in DLBCL announced

50:50 co-development Genmab and AbbVie

Anti-tumor activity

• • 86% ORR in FL ≥ 0.76mg

• • 60% ORR, incl. 3 pts who failed prior CAR-T treatment, in DLBCL/HGBCL ≥12 mg

• • Emerging prelim. data highly encouraging with substantial single-agent efficacy

• • Induces rapid and deep responses in heavily pretreated pts with B-NHL across different subtypes

Safety

• • No DLTs observed; MTD has not been reached

• • No treatment-related deaths

• • No discontinuation due to AEs unrelated to disease progression

• • No Grade ≥ 3 CRS events observed

DuoHexaBody-CD37 (GEN3009)

Building Our Pipeline: First DuoHexaBody in the Clinic

Combination of DuoBody & HexaBody platforms

Novel target for hematologic malignancies

Unique mechanism-of-action

Dose escalation ongoing

50:50 co-development Genmab and AbbVie

DuoBody-CD3x5T4 (GEN1044)

Latest in the Clinic

Based on proprietary DuoBody technology

CD3 bispecific, T cell mediated cytotoxicity of 5T4+ tumor cells

5T4 expressed on multiple solid

tumors limited expression in healthy

tissue

Dose-escalation ongoing

50:50 co-development Genmab and AbbVie

DuoBody-PD-L1x4-1BB (GEN1046)

Bispecific Next Generation Checkpoint Immunotherapy

First-in-Class Bispecific antibody targeting PD-L1 & 4-1BB (CD137)

Designed to activate T cells through conditional

4-1BB co-stimulation, while simultaneously

blocking the PD1/PD-L1 axis

Combining T cell stimulation with

checkpoint blockade

Ph 1/2 study ongoing in solid tumors

50:50 co-development Genmab and BioNTech

DuoBody-CD40x4-1BB (GEN1042)

Bispecific Agonistic Antibody

Bispecific antibody targeting CD40 & 4-1BB (CD137)

Conditionally activates T cells and APC in presence of CD40-expressing cells

Phase 1/2 study ongoing in solid tumors

50:50 co-development Genmab and BioNTech

See local country prescribing information for approved indications

HexaBody-DR5/DR5 (GEN1029)

First HexaBody in Clinical Development

Targets 2 distinct DR5 epitopes

HexaBody platform - DR5 clustering & DR5 agonist activity

First 100% Genmab-owned HexaBody product in

clinic

Phase 1/2 study ongoing in multiple solid tumors

2020 Guidance: Recurring Revenue Growth and Focused Investments

*2020 Guidance - November 4, 2020 / USD 1.00 = DKK 6.50.

• • DARZALEX royalties of ~DKK 4.1bn to ~DKK 4.5bn to drive recurring revenue growth

• • Nearly 90% of USD 750M upfront from AbbVie collab. recognized immediately

• • Growth in operating expenses driven by expanding and accelerating our clinical pipeline

DARZALEX Sales of USD 3.9bn - USD 4.2bn

• • Significant opportunity for growth in 1L MM market

• • SubQ DARZALEX approvals in H1 in U.S. & EU

• • Market share gain in the U.S. and RoW driven by uptake in all lines of treatment

• • 8 approved indications in U.S., late stage to 1L MM

Key 2020 Priorities

Building a Strong Differentiated Product Pipeline

Priority

•  Targeted Milestones

Genmab proprietary* products

•  » Tisotumab vedotin1 - Phase 2 innovaTV 204 safety & efficacy analysis in recurrent/metastatic cervical cancer and engage U.S. FDA for BLA submission subject to trial results

** ***

• » Tisotumab vedotin - data on other solid tumor types

• » Enapotamab vedotin - data to support late stage development

  Daratumumab4

  •       

• » Epcoritamab (DuoBody-CD3xCD20)2 Phase 1/2 - decision on recommended Phase 2 dose & initiate expansion cohorts

• » HexaBody-DR5/DR5 Phase 1/2 - advance dose escalation

• » DuoBody-PD-L1x4-1BB3 Phase 1/2 - initiate expansion cohorts

• » DuoBody-PD-L1x4-1BB initial data in H2 2020

• » File INDs and/or CTAs for 2 new products

• » U.S. FDA and EMA decision on Phase 3 COLUMBA multiple myeloma SubQ submission

• » sBLA and MAA Submission Phase 3 ANDROMEDA amyloidosis

• » sBLA and MAA submission Phase 3 APOLLO multiple myeloma

Ofatumumab5

• » U.S. FDA decision on regulatory dossier submission in multiple sclerosis

  Teprotumumab6

•  » U.S. FDA decision on Phase 3 OPTIC active thyroid eye disease submission

*Certain product candidates in development with partners, as noted. **Data anticipated in 2021 ***Development will not advance 1. 50:50 dev. w/ Seagen; 2. 50:50 dev w/ AbbVie; 3. 50:50 dev. w/ BioNTech; 4. In dev. by Janssen; 5. In dev. by Novartis; 6. In dev. by Horizon Therapeutics

Delivering on Genmab's Promise: Innovating Antibodies, Improving Lives

Pipeline of 1st-in-class / best-in-class therapies advancing through clinic

Unique R&D engine & strategic alliances

Creating Substantial

Value

World-class team with track record of successSignificant earnings potential from marketed products

Innovating Antibodies, Improving Lives

Appendix

A Leading International Biotech With Large Free Float

As of September 30, 2020

Genmab & AbbVie: Collaboration Overview

A broad, long-termoncology collaboration with Genmab and AbbVie working together to jointly make all strategy, clinical development and commercialization decisions

*Source: Company information and filings.

50/50 partnership across three clinical next-generation bispecific antibody product candidates (epcoritamab, DuoHexaBody-CD37, DuoBody-CD3x5T4)

Genmab to book epcoritamab sales in the U.S. and Japan; AbbVie to commercialize epcoritamab RoW - Genmab to receive tiered royalties on RoW net sales

Fourth* largest oncology partnership with total potential value ~USD 3.9bn (up-front cash + milestone payments) to Genmab

Advancing Pipeline: Delivering on Our Promise & Creating Value Accelerating Development of Potential "Next Winners"

DuoBody-CD3xCD20 (epcoritamab)

• • Potential best-in-class: SubQ administration

• • Pre-clinical / preliminary clinical data shows encouraging safety & efficacy

• • Expeditious and comprehensive clinical development plan

• • RP2D decision & expansion cohorts initiation

• • 50:50 AbbVie

DuoBody-PD-L1x4-1BB (GEN1046)

• • Potential first-in-class: Next generation IO

• • Unmet medical need

• • FiH clinical study: escalation phase is ongoing

  Delivering on Genmab's

• • 50:50 BioNTech

Promise for Patients

Advancing Pipeline: Delivering on Our Promise & Creating Value

Bolstering early stage portfolio

Delivering on Genmab's Promise to Patients

Enhancing clinical development capabilities

Innovation Powerhouse:

Cutting Edge Proprietary Technologies

Technology

Principle

Applications

DuoBodyBispecific antibodies

Dual targeting

Target-mediated enhanced hexamerizationEnhanced potency

Bispecific antibodies with target-Dual targeting + enhanced potency

Two co-dependent antibodiesDual targeting + enhanced potency & selectivity

Innovative Clinical and Pre-Clinical Pipeline Genmab's Proprietary1 Products

Product

TargetDeveloped By Disease IndicationsMost Advanced Development Phase

Pre-Clinical

1

1/2

Tisotumab vedotin

TF

50:50 Genmab Cervical cancer / Seattle

GeneticsEpcoritamab (DuoBody-CD3xCD20)CD3, CD20 50:50 Genmab / AbbVie

DuoBody-PD-L1x4-1BB (GEN1046)

PD-L1, 4-1BB

50:50 Genmab / BioNTech

HexaBody-DR5/DR5 (GEN1029)

DR5

Genmab

DuoBody-CD40x4-1BB (GEN1042)

CD40, 4-1BB

50:50 Genmab / BioNTech

DuoHexaBody-CD37 (GEN3009)

CD37

50:50 Genmab / AbbVie

DuoBody-CD3x5T4 (GEN1044)

CD3, 5T4

50:50 Genmab / AbbVie

IND/CTAs in 2020

HexaBody-CD38 (GEN3014)2

GenmabOvarian cancer

Solid tumors

Hematological malignancies

Solid tumors

Solid tumors

Solid tumors

Hematologic malignancies

Solid tumors

1Certain product candidates in development with partners, as noted. 2Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc

2

3

Approved

Products Created by Genmab*

Including Proposed Label Expansions for Marketed Products

Product

TargetDeveloped ByDisease Indications

Most Advanced Development Phase

Pre-ClinicalDARZALEX (daratumumab) & DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)

DaratumumabCD38

Janssen (Tiered royalties to Genmab on net global sales)Kesimpta (ofatumumab)CD20

Novartis (Royalties to Genmab on net global sales)Arzerra (ofatumumab)CD20

Novartis

TEPEZZA (teprotumumab-trbw)TeprotumumabIGF-1R

Horizon Therapeutics (under sublicense from Roche, royalties to Genmab on net global sales)

*Out-licensed products marketed by partner 1See local country prescribing information for precise indications, 2Not in active development

1

1/2

2

3

Approved

Partner-owned Products Incorporating Genmab's Innovation*

Product

TargetDeveloped By

Disease Indications

Pre-Clinical

Amivantamab (JNJ-61186372)

EGFR, cMetJanssen

Teclistamab

(JNJ-64007957)

BCMA, CD3

Janssen

PRV-015

(AMG 714)

IL-15

Provention Bio

Camidanlumab tesirine

(ADCT-301)

CD25

ADC Therapeutics

Mim8

FIX(a), FXNovo Nordisk

Talquetamab

(JNJ-64407564)

GPRC5D, CD3

Janssen

JNJ-63709178

CD123, CD3

Janssen

JNJ-63898081

PSMA, CD3

Janssen

JNJ-67571244

CD33, CD3

Janssen

JNJ-70218902

UndisclosedJanssen

HuMax-IL8

Lu AF82422

IL8 alpha-Synuclein

BMS

LundbeckNon-small-cell lung cancer (NSCLC)

Relapsed /Refractory Hodgkin Lymphoma

Solid tumors

Healthy volunteers & hemophilia A

Relapsed or refractory MM

Acute Myeloid Leukemia (AML)

Solid tumors

Relapsed or refractory AML or MDS

Solid tumors

Advanced cancers

Parkinson's disease

*Out-licensed Products under development by a third-party incorporating Genmab technology and innovation

Most Advanced Development Phase

1

1/2

2

3

Approved

Solid Foundation Built on a Differentiated Pipeline Tisotumab Vedotin Clinical Program

• • Basket study

• • 2° endpoints: Safety, disease control rate, duration of response, time to response, PFS, OS

• • Ovarian cancer, fallopian tube cancer, peritoneal cancer

• • 2 schedules: q3wk & dose dense

• • 1° endpoints: Safety & ORR

Tisotumab Vedotin Cervical Cancer Market Size

In developed countries, incidence rates are low (<7.9 per 100,000 women) compared with developing countries in sub-Saharan Africa and Central and South America, where incidence is especially high (>30 per 100,000 women)5

*Europe is defined as the 40 countries in the four United Nations-defined areas of Europe and the European Union (EU-27).

References: 1. American Cancer Society 2. .EUCAN (2012) 3. Centers for Disease Control and Prevention. Cervical Cancer Statistics (2017) 4. UpToDate.

5. Ginsburg O et al. Lancet 2017 6. HPV Information Centre Japan (2017)

HexaBody-CD38 (GEN3014)

Expanding the Potential of CD38 Antibodies

Covering All Stages of MM and Beyond: Key Ongoing* Industry Sponsored Trials

Disease

Therapy

Development Phase

Pre-Clinical

High Risk Smoldering MMFront line MM (transplant & non-transplant)

Relapsed or Refractory MMALL

Subcutaneous

Monotherapy

Dara + VRd

Dara + VMP (Asia Pacific)

Dara + VRd

Dara + R (maintenance)

Dara + combinations

Dara + I.O. (PD1 & PDL1)

Dara + SoC chemo

•  Fully recruited

V = Velcade® , MP = melphalan-prednisone , T = thalidomide d = dexamethasone, R = Revlilmid®, K = Kyprolis®, Pom = Pomalyst®

*Does not include trials that may still be ongoing but have clinical data and/ or are the basis for an existing approval.

1

1/2

2

3

Daratumumab Efficacy in Newly Diagnosed Multiple Myeloma Updated Phase 3 MAIA Trial (D+Rd, NTE): ASH Dec 2019

D = daratumumab; R = lenalidomide; d = dexamethasone; PFS = progression free survival; MRD - minimal residual disease

• • Median PFS not reached in D-Rd arm

• • MRD-negativity significantly higher with D-Rd vs. Rd (29% vs 9%; P<0.0001)

• • No new safety concerns

• • Results continue to support use of D-Rd in 1st line treatment of TIE pts with NDMM

Janssen Sponsored Phase 3 & 4

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier	Phase	Sponsor	Indication	Therapy
NCT03768960	4	J&J Private Ltd	Relapsed or Refractory MM	Daratumumab (MMY4008)
NCT02252172	3	Janssen	Untreated MM	Daratumumab + Rd (MAIA)
NCT02195479	3	Janssen	Untreated MM	Daratumumab + VMP (ALCYONE)
NCT02541383	3	Janssen	Untreated MM	Daratumumab + VTd (CASSIOPEIA)
NCT02076009	3	Janssen	Relapsed or Refractory MM	Daratumumab + Rd (POLLUX)
NCT02136134	3	Janssen	Relapsed or Refractory MM	Daratumumab + Vd (CASTOR)
NCT03180736	3	Janssen	Relapsed or Refractory MM	Daratumumab + Pom-d (APOLLO)
NCT03201965	3	Janssen	Amyloidosis	Daratumumab + CyBorD (ANDROMEDA)
NCT03217812	3	Janssen	Untreated MM	Daratumumab + VMP (Asia Pacific) (OCTANS)
NCT03234972	3	Janssen	Relapsed or Refractory MM	Daratumumab + Vd vs Vd (LEPUS)
NCT03277105	3	Janssen	Relapsed or Refractory MM	Daratumumab SubQ vs IV (COLUMBA)
NCT03301220	3	Janssen	Smoldering MM	Daratumumab SubQ (AQUILA)
NCT03652064	3	Janssen	Untreated MM	Daratumumab + VRd (CEPHEUS)
NCT03710603	3	Janssen/EMN	Untreated MM	Daratumumab + VRd (PERSEUS)
NCT03901963	3	Janssen	Untreated MM / Maintenance	Daratumumab + R (AURIGA)

Janssen Sponsored Phase 1 & 2

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier

NCT03384654

NCT02951819

NCT02874742

NCT02316106

NCT02927925

NCT03412565

NCT03871829

NCT03011034

NCT01615029

NCT02852837

NCT02519452

NCT02918331

NCT03242889

NCT01998971

NCT04108195

NCT04121260

Phase

Sponsor Janssen Janssen Janssen Janssen Janssen Janssen Janssen Janssen Janssen Janssen Janssen Janssen Janssen

Indication

2

2

2

Relapsed / Refractory ALL / LL Untreated and Relapsed MM Untreated MM

2

2

Smoldering MM NKTCL, Nasal Type

2

2

Newly diag. & relapsed / refractory MM Dara retreatment

2

MDS

1/2

1

1

1

Relapsed and Refractory MM Relapsed or Refractory MM Relapsed or Refractory MM Untreated MM

1

Relapsed or Refractory MM

1

Janssen

Various MM

1

1

Janssen Janssen

Multiple Myeloma Multiple Myeloma

Therapy

Dara + Vincristine + Prednisone + Doxorubicin (DELPHINUS) Daratumumab + CyBorD (LYRA)

Daratumumab + VRd (GRIFFIN) Monotherapy (CENTAURUS) Monotherapy (VOLANS)

Daratumumab SubQ + Rd, VMP & VRd (PLEIADES) Daratumumab SubQ+ Kd vs Kd (LYNX) Daratumumab (or talacotuzumab) (MDS2002) Daratumumab + Rd (GEN503)

Monotherapy (in China) (MMY1003) Monotherapy, subcutaneous (PAVO) Daratumumab + Rd (Japan) (MMY1006) Daratumumab subq (Japan) (MMY1008)

Daratumumab + backbone regimens (Vd, VMP, VTd, Pom-d, Kd, KRd) (EQUULEUS)

Daratumuamb + either talquetamab or teclistamab (MMY1002) Subcutaneous monotherapy (in China) (MMY1010)

Other Industry Sponsored Trials

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov IdentifierPhase

NCT03158688 3

NCT01946477 2

NCT02807454 2

NCT03439293 2

NCT03314181 2

NCT02807558 2

NCT02773030 1/2

NCT02343042 1/2

NCT03481556 1/2

NCT01592370 1/2

NCT03837509 1/2

NCT03989414 1/2

NCT02431208 1

Sponsor

Amgen Celgene Celgene Takeda AbbVie

Syros Pharma Celgene Karyopharm

Oncopeptides AB

Indication

Relapsed or Refractory MM Relapsed or Refractory MM Relapsed and Refractory MM Relapsed or Refractory MM Relapsed or Refractory MM AML or MDS

Relapsed or Refractory MM Relapsed or Refractory MM

Relapsed or Refractory MM

BMS Incyte Celgene Roche

Relapsed or Refractory MM Relapsed or Refractory MM Various MM

Resistant or Refractory MM

Therapy

Daratumumab + Kd (CANDOR) Daratumumab + Pom-d Daratumumab + Imfinzi (FUSION) Daratumumab + NINLARO (ixazomib) + Dex Daratumumab + Venetoclax + Dex (w/ or w/out bortezomib) Daratumumab + SY-1425

Daratumumab + CC-220 + Dex Daratumumab + Selinexor + Dex (STOMP)

Daratumumab + Melflufen + Dex (ANCHOR)

Daratumumab + nivolumab

Daratumumab + INCB001158 Daratumumab + CC-92480 Daratumumab + Tecentriq (atezolizumab)

NCT03068351 1

Roche

Resistant or Refractory MM

Daratumumab + RO6870810

NCT04045028 1

NCT04136756 1

Genentech Nektar Thera.

Relapsed or Refractory MM Salvage for MM

Daratumumab + tiragolumab Daratumumab + NKTR-255

www.genmab.com